Fans of All Ordinaries Index (ASX: XAO) biotechnology share Mesoblast Ltd (ASX: MSB) may have been on tenterhooks today. The company entered a trading halt shortly after the market opened, citing âa proposed placement of securities to targeted investorsâ.
But the short, roughly 30-minute window in which Mesoblast shares traded today saw the market bidding them lower. The companyâs share price is halted at 99 cents â 1% lower than it closed Wednesdayâs session.
For comparison, the ASX All Ords is up 0.04% at the time of writing.
Letâs take a closer look at whatâs happening (or not happening) with Mesoblast shares on Thursday.
Mesoblast in trading halt amid placement
The Mesoblast share price isnât going anywhere this afternoon as the company seemingly undergoes a capital raise.
Of course, thatâs likely left investors itching for more information. And they might be kept waiting.
The company has requested that the trading halt continue until the market opens on Monday unless it releases another announcement sooner.
The last time the market was given a chance to delve into the companyâs balance sheet was in late February.
Then, it revealed it had US$67.6 million of cash on hand and the option to draw an additional US$40 million from existing financing facilities subject to certain milestones.
It also used US$16.5 million of cash in operating activities in the second quarter of financial year 2023, posting a US$24.5 million post-tax loss for the period.
The last time Mesoblast underwent a placement was in August 2022. Then, it raised US$45 million by offering new shares for 75 cents apiece to major shareholders.
Mesoblast share price snapshot
The Mesoblast share price has had a wild ride in recent months.
The stock reached a high of $1.33 in February, a 118% recovery from its June 2022 low of 61 cents.
Itâs currently 14% higher than it was at the start of 2023. Though, itâs fallen 13% since this time last year.
Meanwhile, the All Ords has gained 6% year to date and is down 4% over the last 12 months.
The post Hereâs why Mesoblast shares are in a trading halt today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast Limited right now?
Before you consider Mesoblast Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of April 3 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Why 29Metals, Allkem, Alliance, and Rio Tinto shares are falling today
- Why Bank of Queensland, Link, Silk Laser, and Zip shares are pushing higher
- How might the latest RBA changes impact ASX 200 investors?
- Could CBA be about to add $1 billion to its loan book?
- Could the Woodside share price face ‘long-term harm’ from this government tax plan?
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/FYEf5t9
Stock Pick 